PT3134119T - Tratamento do cancro - Google Patents

Tratamento do cancro

Info

Publication number
PT3134119T
PT3134119T PT15729222T PT15729222T PT3134119T PT 3134119 T PT3134119 T PT 3134119T PT 15729222 T PT15729222 T PT 15729222T PT 15729222 T PT15729222 T PT 15729222T PT 3134119 T PT3134119 T PT 3134119T
Authority
PT
Portugal
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PT15729222T
Other languages
English (en)
Portuguese (pt)
Inventor
Andre Martini Jean-Francois
Christo Tarazi Jamal
Andrew Williams James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT3134119T publication Critical patent/PT3134119T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT15729222T 2014-04-24 2015-04-16 Tratamento do cancro PT3134119T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24

Publications (1)

Publication Number Publication Date
PT3134119T true PT3134119T (pt) 2018-11-07

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15729222T PT3134119T (pt) 2014-04-24 2015-04-16 Tratamento do cancro

Country Status (23)

Country Link
US (2) US20170184602A1 (enExample)
EP (1) EP3134119B1 (enExample)
JP (1) JP6603474B2 (enExample)
KR (1) KR101943177B1 (enExample)
CN (1) CN106233143B (enExample)
AR (1) AR100169A1 (enExample)
AU (3) AU2015249513A1 (enExample)
BR (1) BR112016024143A2 (enExample)
CA (1) CA2946362C (enExample)
CY (1) CY1120731T1 (enExample)
DK (1) DK3134119T3 (enExample)
ES (1) ES2691213T3 (enExample)
HU (1) HUE040167T2 (enExample)
IL (1) IL247859B (enExample)
MX (1) MX375794B (enExample)
PL (1) PL3134119T3 (enExample)
PT (1) PT3134119T (enExample)
RU (1) RU2651469C1 (enExample)
SG (1) SG11201607918TA (enExample)
SI (1) SI3134119T1 (enExample)
TR (1) TR201815682T4 (enExample)
TW (1) TWI568439B (enExample)
WO (1) WO2015162532A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
EP3820520A4 (en) 2018-07-12 2022-05-11 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
JP2021532084A (ja) 2018-07-12 2021-11-25 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシン経路活性化を有する癌を検出および治療するための方法
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
CA3252723A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts USE OF A REP PROTEIN BMMF1 AS A DIAGNOSTIC MARKER FOR LUNG CANCER
CA3252712A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts USE OF REP BMMF1 PROTEIN AS A DIAGNOSTIC MARKER FOR PANCREATIC CANCER AND TYPE 2 DIABETES
WO2024026407A1 (en) * 2022-07-28 2024-02-01 The Board Of Regents Of The University Of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1678327A4 (en) 2003-10-16 2007-10-10 Genomic Health Inc QRT-PCR TEST SYSTEM FOR GENE EXPRESSION PROFILING
EP2947160B1 (en) * 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CA2626019A1 (en) * 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
WO2008013912A1 (en) * 2006-07-28 2008-01-31 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
WO2008066755A2 (en) * 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
WO2011003911A1 (en) * 2009-07-08 2011-01-13 Vladimir Lazar Method for predicting efficacy of drugs in a patient
WO2011033006A1 (en) * 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
US9046534B2 (en) * 2011-10-04 2015-06-02 Invivis Pharmaceuticals Inc. Methods and systems for identifying and treating anti-progestin sensitive tumors
MX356802B (es) 2012-01-13 2018-06-13 Genentech Inc Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.

Also Published As

Publication number Publication date
EP3134119B1 (en) 2018-08-22
TR201815682T4 (tr) 2018-11-21
RU2651469C1 (ru) 2018-04-19
CN106233143B (zh) 2020-01-21
US20170184602A1 (en) 2017-06-29
SG11201607918TA (en) 2016-11-29
CY1120731T1 (el) 2019-12-11
CN106233143A (zh) 2016-12-14
AR100169A1 (es) 2016-09-14
US20190331687A1 (en) 2019-10-31
AU2015249513A1 (en) 2016-10-06
DK3134119T3 (en) 2018-10-22
PL3134119T3 (pl) 2018-12-31
TWI568439B (zh) 2017-02-01
HK1231561A1 (zh) 2017-12-22
CA2946362A1 (en) 2015-10-29
KR20160134817A (ko) 2016-11-23
TW201545747A (zh) 2015-12-16
IL247859A0 (en) 2016-11-30
MX375794B (es) 2025-03-07
AU2018203086A1 (en) 2018-05-24
MX2016013910A (es) 2017-01-11
JP2015210268A (ja) 2015-11-24
HUE040167T2 (hu) 2019-02-28
BR112016024143A2 (pt) 2017-08-15
EP3134119A1 (en) 2017-03-01
SI3134119T1 (sl) 2018-11-30
IL247859B (en) 2020-07-30
AU2020200237A1 (en) 2020-02-06
CA2946362C (en) 2019-03-12
KR101943177B1 (ko) 2019-01-28
JP6603474B2 (ja) 2019-11-06
ES2691213T3 (es) 2018-11-26
WO2015162532A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
ZA201702382B (en) Combination therapy for cancer
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL248856A0 (en) New treatment
IL249898A0 (en) Combined cancer treatment
IL247859A0 (en) Cancer treatment
IL246761A0 (en) Combined cancer treatment
GB201408297D0 (en) Treatment of cancer
GB201409363D0 (en) Skin cancer treatment
IL260814A (en) Cancer treatment
GB201522433D0 (en) Cancer treatment
GB201508480D0 (en) Cancer
GB201411027D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
GB201412411D0 (en) Treatment
GB201411884D0 (en) Cancer therapy
GB201413317D0 (en) Atheroscierosis treatment
GB201409362D0 (en) Treatment of cancer
GB201412410D0 (en) Treatment
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201400241D0 (en) Treatment
GB201400240D0 (en) Treatment
GB201400239D0 (en) Treatment
GB201400238D0 (en) Treatment
GB201400235D0 (en) Treatment